FDA Grants Priority Review to Dupixent for Uncontrolled Chronic Obstructive Pulmonary Disease

The FDA has assigned a supplemental Biologics License Application submitted by Regeneron and Sanofi for Dupixent in the treatment of COPD with type 2 inflammation with a PDUFA date of June 27, 2024.

Source link
#FDA #Grants #Priority #Review #Dupixent #Uncontrolled #Chronic #Obstructive #Pulmonary #Disease